Global Monoclonal Antibody Custom Service Market Opportunities and Forecast 2020-2027

1 Report Prologue 11

2 Introduction 15

• 2.1 Scope of Study 15
• 2.2 Research Objective 15
• 2.3 Assumptions & Limitations 15
  • 2.3.1 Assumptions 15
  • 2.3.2 Limitations 15
• 2.4 Market Structure 16

3 Research Methodology 17

• 3.1 Primary Research 18
• 3.2 Secondary Research 18
• 3.3 Market Size Estimation 18
  • 3.3.1 Market share analysis 19
• 3.4 Market Pricing Approach 20

4 Market Dynamics 21

• 4.1 Introduction 21
• 4.2 Drivers 22
  • 4.2.1 Increasing investment in research & development (weightage 45%) 22
  • 4.2.2 Increasing prevalence of chronic diseases and infection (weightage 40%) 23
  • 4.2.3 Increasing prevalence of immunological diseases (weightage 15%) 24
• 4.3 Restraints 25
  • 4.3.1 High cost of the monoclonal antibody services 25
• 4.4 Opportunities 26
• 4.5 Macroeconomic Indicators 26

5 Market Factor Analysis 28

• 5.1 Value Chain Analysis 28
• 5.2 Porter’s Five Forces Model 29
  • 5.2.1 Bargaining power of suppliers 29
  • 5.2.2 Bargaining power of buyers 30
  • 5.2.3 Threat of new entrants 30
  • 5.2.4 Threat of substitutes 30
  • 5.2.5 Intensity of rivalry 30
• 5.3 Investment Opportunity Analysis 31
• 5.4 Technology Trend Analysis 31

6 Global Monoclonal Antibody Custom Service Market, by Type 32

• 6.1 Introduction 32
• 6.2 Rat Custom Monoclonal Antibody 33
• 6.3 Rabbit Custom Monoclonal Antibody 35
• 6.4 Others 36

7 Global Monoclonal Antibody Custom Service Market, by Application 37

• 7.1 Introduction 37
• 7.2 Diagnostic Application 39
  • 7.2.1 Biochemical Analysis 39
    • 7.2.1.1 Pregnancy 39
    • 7.2.1.2 Cancer 39
    • 7.2.1.3 Hormonal Disorder 39
    • 7.2.1.4 Infectious Diseases 40
  • 7.2.2 Diagnostic Imaging 40
    • 7.2.2.1 Cardiovascular Diseases 40
    • 7.2.2.2 Cancer 41
    • 7.2.2.3 Bacterial Infections 41

8 Global Monoclonal Antibody Custom Service Market, by End User 45

• 8.1 Introduction 45
• 8.2 Hospitals 47
• 8.3 Research & Academic Laboratories 48
• 8.4 Pharmaceutical & Biotechnology Companies 49

9 Global Monoclonal Antibody Custom Service Market, by Region 50

• 9.1 Introduction 50
• 9.2 Americas 52
  • 9.2.1 US 55
  • 9.2.2 Canada 57
  • 9.2.3 South America 59
• 9.3 Europe 62
  • 9.3.1 Germany 65
  • 9.3.2 France 67
  • 9.3.3 UK 69
  • 9.3.4 Italy 71
  • 9.3.5 Spain 73
  • 9.3.6 Rest of Western Europe 75
  • 9.3.7 Eastern Europe 77
• 9.4 Asia Pacific 80
  • 9.4.1 Japan 83
  • 9.4.2 China 85
  • 9.4.3 India 87
  • 9.4.4 Australia 89
  • 9.4.5 Republic of Korea 91
  • 9.4.6 Rest of Asia Pacific 93
• 9.5 Middle East & Africa 96
  • 9.5.1 Middle East 99
  • 9.5.2 Africa 101

10 Company Landscape 104

• 10.1 Introduction 104
• 10.2 Company Share Analysis 104
• 10.3 Key Developments 105

11 Company Profiles 107

• 11.1 Thermo Fisher Scientific 107
  • 11.1.1 Company Overview 107
  • 11.1.2 Financials 107
  • 11.1.3 Products 107
  • 11.1.4 Strategy 107
  • 11.1.5 Key Developments 107
• 11.2 GenScript 108
  • 11.2.1 Company Overview 108
  • 11.2.2 Financials 108
  • 11.2.3 Products 108
  • 11.2.4 Strategy 108
  • 11.2.5 Key Developments 108
• 11.3 Abnova Corporation 109
  • 11.3.1 Company Overview 109
  • 11.3.2 Financials 109
  • 11.3.3 Products 109
  • 11.3.4 Strategy 109
  • 11.3.5 Key Developments 109
• 11.4 Creative-Biolabs 110
  • 11.4.1 Company Overview 110
  • 11.4.2 Financials 110
  • 11.4.3 Products 110
  • 11.4.4 Strategy 110
  • 11.4.5 Key Developments 110
• 11.5 Abcam plc 111
  • 11.5.1 Company Overview 111
  • 11.5.2 Financials 111
  • 11.5.3 Products 111
  • 11.5.4 Strategy 111
  • 11.5.5 Key Developments 111
• 11.6 ProMab Biotechnologies Inc 112
  • 11.6.1 Company Overview 112
  • 11.6.2 Financials 112
  • 11.6.3 Products 112
  • 11.6.4 Strategy 112
  • 11.6.5 Key Developments 112
• 11.7 Envigo 113
  • 11.7.1 Company Overview 113
  • 11.7.2 Financials 113
  • 11.7.3 Products 113
  • 11.7.4 Strategy 113
  • 11.7.5 Key Developments 113

12 Conclusion 114

• 12.1 Key Findings 114
  • 12.1.1 CEO’s Viewpoint 114
  • 12.1.2 Unmet Needs 114
  • 12.1.3 Key Companies to Watch 114

13 Appendix 115

• 13.1 Discussion Blue Print 115
• 13.2 References 117